Atossa Therapeutics (YAG) Stock Statistics & Valuation Metrics
Total Valuation
Atossa Therapeutics has a market cap or net worth of EUR 20.42M. The enterprise value is -EUR 9.01M.
- Market Cap
- EUR 20.42M
- Enterprise Value
- -EUR 9.01M
Share Statistics
Atossa Therapeutics has 9,979,298 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 9,979,298
- Owned by Insiders
- 2.17%
- Owned by Institutions
- 31.50%
Financial Efficiency
Atossa Therapeutics’s return on equity (ROE) is -0.88 and return on invested capital (ROIC) is -94.38%.
- Return on Equity (ROE)
- -0.88
- Return on Assets (ROA)
- -0.73
- Return on Invested Capital (ROIC)
- -94.38%
- Return on Capital Employed (ROCE)
- -0.94
- Revenue Per Employee
- 0
- Profits Per Employee
- -2.17M
- Employee Count
- 16
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Atossa Therapeutics is -0.54. Atossa Therapeutics’s PEG ratio is 0.02.
- PE Ratio
- -0.54
- PS Ratio
- 0.00
- PB Ratio
- 0.77
- Price to FCF
- -0.65
- Price to Operating Cash Flow
- -0.58
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Atossa Therapeutics had revenue of 0 and earned -34.77M in profits. Earnings per share was -4.04.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -37.14M
- Pretax Income
- -34.77M
- Net Income
- -34.77M
- EBITDA
- -34.75M
- Earnings Per Share (EPS)
- -4.04
Cash Flow
In the last 12 months, operating cash flow was -35.77M and capital expenditures -14,000, giving a free cash flow of -35.78M billion.
- Operating Cash Flow
- -35.77M
- Free Cash Flow
- -35.78M
- Free Cash Flow per Share
- -4.02
Dividends & Yields
Atossa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -154.56%
- Earnings Yield
- -182.45%
Stock Price Statistics
- Beta
- 1.24
- 52-Week Price Change
- -82.40%
- 50-Day Moving Average
- 2.08
- 200-Day Moving Average
- 4.00
- Relative Strength Index (RSI)
- 44.71
- Average Volume (3m)
- 705
Important Dates
Atossa Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 07, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Atossa Therapeutics as a current ratio of 5.53, with Debt / Equity ratio of 0.00%
- Current Ratio
- 5.53
- Quick Ratio
- 5.53
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.19
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Atossa Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Atossa Therapeutics EV to EBITDA ratio is 0.08, with an EV/FCF ratio of 0.08.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.08
- EV to Free Cash Flow
- 0.08
- EV to Operating Cash Flow
- 0.08
Balance Sheet
Atossa Therapeutics has EUR 26.09M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 26.09M billion.
- Cash & Marketable Securities
- EUR 26.09M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 26.09M
- Net Cash Per Share
- EUR 2.61
- Tangible Book Value Per Share
- EUR 3.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Atossa Therapeutics is EUR 15.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 15.67
- Price Target Upside
- 691.39% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -20.40%
